U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT07545967) titled 'Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy' on April 15.
Brief Summary: To evaluate the safety and tolerability of re-irradiation combined with chidamide in patients with recurrent head and neck squamous cell carcinoma after radiotherapy.
Study Start Date: July 01, 2026
Study Type: INTERVENTIONAL
Condition:
Head and Neck Squamous Cell Carcinoma HNSCC
Intervention:
DRUG: Chidamide
Dose Escalation Design:
Chidamide will be administered orally according to the protocol-specified schedule(20mg BIW).
Administration Schedule:
Chidamide treatmen...